Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program – Ketamine-Assisted Therapy for Alcohol Use Disorder
Ryan Allway July 5th, 2022 Psychedelics, Top News Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III Toronto, Ontario–(Newsfile Corp. – July 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )